Jpmorgan Chase & CO Biovie Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Biovie Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,672 shares of BIVI stock, worth $35,101. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,672
Previous 2,442
418.92%
Holding current value
$35,101
Previous $1,000
400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BIVI
# of Institutions
45Shares Held
4.73MCall Options Held
17.2KPut Options Held
27K-
Altium Capital Management LP New York, NY1.98MShares$5.49 Million0.42% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ733KShares$2.03 Million19.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA568KShares$1.57 Million0.0% of portfolio
-
Swisspartners Ltd. Vaduz, N2294KShares$815,3382.92% of portfolio
-
Geode Capital Management, LLC Boston, MA232KShares$641,6870.0% of portfolio
About BIOVIE INC.
- Ticker BIVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,165,300
- Market Cap $83.6M
- Description
- BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...